Navigation Links
Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
Date:2/15/2008

NEW BRUNSWICK, N.J., Feb. 15 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT) today reported financial results for the three months ended December 31, 2007.

Net loss for the three month period ended December 31, 2007 was $1.3 million, or $0.07 per share, compared with a net loss of $1.1 million, or $0.07 per share, for the three month period ended December 31, 2006. This increase in net loss was primarily the result of a decrease in revenue and an increase in expenses associated with the outstanding convertible notes that were issued during the current fiscal year, which was partially offset by a decrease in operating expenses.

Quarterly and Recent Highlights

-- Senesco closed on an additional gross amount of $5.5 million of its

previously announced private placements with YA Global Investments, LP

("YA Global") and Stanford Venture Capital Holdings, Inc. ("Stanford").

Through January 31, 2008, Senesco has now closed on an aggregate of

$7 million of the $10 million private placements of secured convertible

debentures and warrants and has met the three triggering milestones

necessary in order to fix the conversion price of the convertible notes

issued to YA Global and Stanford at $0.90 per share of common stock.

-- Senesco selected Cato Research, a leading contract research

organization ("CRO"), to assist the Company with its goal of initiating

a clinical trial.

-- Senesco initiated and announced the results of certain preclinical

animal studies focused on multiple myeloma. In the studies, SCID

(severe combined immunodeficiency) mice were injected subcutan
'/>"/>

SOURCE Senesco Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
2. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
7. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
8. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
9. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
10. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
11. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 A study has been launched to ... 1 track could help to tackle the problem of obesity. ... (a GP surgery based in Stowmarket) and academics at University ... Telemetry technology, which is inspired by equipment used to ...
(Date:1/15/2014)... 15, 2014 The Microcompetition with Foreign DNA ... One of these latent viruses is the Epstein Barr Virus ... Rheumatoid arthritis (RA) is a chronic inflammatory disease that destroys ... found that RA patients have high concentrations of EBV DNA ...
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... Therapeutics, Inc.,(Nasdaq: TPTX ) today announced that ... in certain royalty amounts that may become payable to ... and tezampanel,should either or both gain regulatory approval. Specifically, ... points and the middle tier,royalty rate will be reduced ...
... Pa., Nov. 25 Tengion Inc., a clinical stage regenerative medicine ... that Steven Nichtberger, M.D., President and Chief Executive Officer of Tengion, ... Tuesday, December 2, 2008 at 9:50 a.m. EST at The Palace ... , About Tengion , ...
... 25 /PRNewswire-Asia/ -- ScinoPharm, an active,pharmaceutical ingredient (API) ... 7,435,818 entitled "Novel Crystal Forms of Irinotecan,Hydrochloride." The ... hydrochloride and processes for their preparation as well ... of treating,metastatic carcinoma of the colon or rectum ...
Cached Biology Technology:TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel 2ScinoPharm Granted US Patent for Novel Crystal Forms 2
(Date:4/20/2014)... Mothers give a newborn baby a gift of ... system. But antibiotics, used to fend off infection, ... leaving already-vulnerable premature babies more susceptible to dangerous ... neonatology researchers at The Children,s Hospital of Philadelphia ... revealing how gut microbes play a crucial role ...
(Date:4/18/2014)... decades, scientists have used techniques like X-ray crystallography and ... into the atomic structure of molecules, but such efforts ... demand large quantities of a specific molecule and often ... making it all but impossible to peer into the ... those problems may soon be a thing of the ...
(Date:4/18/2014)... Durham, NC Seeds that sprout as soon as they,re ... plants need to be more careful. In the wild, a ... rainy day would risk disaster. More than just an insurance ... out that seed dormancy has long-term advantages too: Plants ... give rise to more species, finds in a team of ...
Breaking Biology News(10 mins):Study of gut microbes, antibiotics: Clues to improving immunity in premature infants 2MRI, on a molecular scale 2MRI, on a molecular scale 3Plants with dormant seeds give rise to more species 2
... antibiotic used to boost organ survival in transplant ... the heart against tissue damage following acute heart ... Journal of Molecular and Cellular Cardiology, the official ... researchers demonstrated for the first time that pretreatment ...
... to change their spots, but corals can change their skeletons, ... composition of the seawater around them. , That's the startling ... in the July issue of the journal Geology. , ... the first known case of an animal altering the composition ...
... University in St. Louis and their collaborators from Taiwan ... varieties and have determined that the crop was domesticated ... Jason Londo, Washington University in Arts & Sciences biology ... Washington University Spencer T. Olin Professor of Biology in ...
Cached Biology News:New study shows antibiotic may protect the heart 2Corals switch skeleton material as seawater changes 2Corals switch skeleton material as seawater changes 3Biologists find regions of rice domestication 2
Mouse Wnt-9b Affinity Purified Polyclonal Ab Keywords: Wnt 9b Protein Family: Cancer Stem Cell Markers, Wnt Ligands...
One-step, microplate or cuvet, colorimetric, linear detection range 0.6 mM to 100 mM. Procedure: 2 min....
One-step, microplate or cuvet, colorimetric, linear detection range 6 mg/dL to 100mg/dL. Procedure: 15 min....
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
Biology Products: